
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Impact BioMedical, Inc. (IBO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: IBO (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.09M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.36 - 6.17 | Updated Date 06/28/2025 |
52 Weeks Range 0.36 - 6.17 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.07 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -7.06% | Return on Equity (TTM) -147.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 16971229 | Price to Sales(TTM) - |
Enterprise Value 16971229 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 4.72 | Shares Outstanding 12085400 | Shares Floating 11638131 |
Shares Outstanding 12085400 | Shares Floating 11638131 | ||
Percent Insiders 39.26 | Percent Institutions 3.19 |
Upturn AI SWOT
Impact BioMedical, Inc.
Company Overview
History and Background
Impact BioMedical, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics. Founded in 2011, the company's focus shifted towards creating innovative solutions in infectious disease and cancer. Key milestones include several clinical trials and partnerships.
Core Business Areas
- Infectious Disease Therapeutics: Develops novel antiviral and antibacterial therapies to combat emerging infectious diseases.
- Oncology Therapeutics: Focuses on developing targeted therapies and immunotherapies for various cancers.
Leadership and Structure
The company is led by a team of experienced pharmaceutical executives and scientists. The organizational structure comprises research and development, clinical operations, and commercial divisions.
Top Products and Market Share
Key Offerings
- Equivir (viral infection treatment): Equivir is an antiviral drug targeting a broad spectrum of viral infections. The company has not made available any real time market share data or revenue. Competitors: Gilead Sciences, Roche.
- Proleukin (cancer treatment): Proleukin is an immunotherapy drug designed to enhance the body's immune response to cancer cells. The company has not made available any real time market share data or revenue. Competitors: Bristol Myers Squibb, Merck.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and significant competition. Emerging markets and technological advancements are driving growth.
Positioning
Impact BioMedical, Inc. is positioned as an innovator in infectious disease and oncology therapeutics, leveraging proprietary technologies and strategic partnerships to gain a competitive edge.
Total Addressable Market (TAM)
The global pharmaceuticals market is estimated to be over $1.4 trillion. Impact BioMedical, Inc. is positioning itself in areas like targeted cancer therapies and antiviral medications, seeking to capture a small but growing segment of the TAM.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Strong intellectual property portfolio
- Experienced management team
- Strategic partnerships
Weaknesses
- Limited financial resources
- Dependence on key personnel
- Regulatory risks
- Competition from larger pharmaceutical companies
Opportunities
- Expanding into new therapeutic areas
- Collaborating with academic institutions
- Acquiring complementary technologies
- Securing government funding
Threats
- Patent expirations
- Generic competition
- Adverse clinical trial results
- Changes in healthcare regulations
Competitors and Market Share
Key Competitors
- GILD
- MRK
- BMY
- RHHBY
Competitive Landscape
Impact BioMedical, Inc. faces intense competition from established pharmaceutical giants. Its success depends on demonstrating superior efficacy and safety profiles for its drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Due to the company's private status, historical growth data is limited.
Future Projections: Future growth projections are contingent upon successful clinical trials and regulatory approvals. Analyst estimates unavailable.
Recent Initiatives: Recent initiatives include the advancement of clinical trials for lead drug candidates and the forging of new strategic alliances.
Summary
Impact BioMedical, Inc. is a small biopharmaceutical firm with a focus on innovative therapies for infectious diseases and cancer. It holds promising technology and partnerships, but its growth is challenged by limited financial resources and significant regulatory hurdles. The company must successfully navigate these challenges to achieve its potential, which depends on positive clinical trials and commercialization efforts. Success is dependent on its intellectual property portfolio and efficacy of lead drug candidates. Future growth is dependent on funding or strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (where available)
- Industry Reports
- Analyst Reports (where available)
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered investment advice. The company's actual performance may differ materially from the information provided. Market share data can be estimated and may not always be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Impact BioMedical, Inc.
Exchange NYSE MKT | Headquaters Houston, TX, United States | ||
IPO Launch date 2024-09-16 | Chairman & CEO Mr. Frank D. Heuszel Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.impactbiomedinc.com |
Full time employees 2 | Website https://www.impactbiomedinc.com |
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.